Kyinno Biotechnology
Private Company
Funding information not available
Overview
Kyinno Biotechnology is a private, early-stage CRO founded in 2020, focusing exclusively on the complex and rapidly evolving fields of cell therapy and immunology. Operating from the biotech hub of Cambridge, MA, the company adopts a services-based business model, generating revenue by supporting the R&D efforts of other therapeutic developers. As a pre-clinical service provider, its success is tied to securing partnerships with biotech and pharma clients, leveraging its specialized technical expertise to navigate the challenges inherent in cell-based therapies. The company is currently in an early revenue phase, building its client base and service portfolio in a competitive CRO landscape.
Technology Platform
Integrated contract research services platform specializing in cell therapy and immunology, encompassing assay development, cell process optimization, analytical testing, and preclinical study management.
Opportunities
Risk Factors
Competitive Landscape
Kyinno competes in a fragmented but competitive CRO landscape. It faces competition from large, diversified players (e.g., LabCorp, IQVIA, Charles River) with broad service offerings, as well as from other specialized cell therapy service providers (e.g., Lonza, Catalent, smaller niche CROs). Differentiation requires demonstrating superior technical expertise, flexibility, and client service in the complex cell therapy domain.